Our ZS experts, Matthew Furlow, Ph.D. and Jedediah Seltzer, Ph.D., recently attended the #ASH24 conference and had the opportunity to speak with Dr. Amitkumar Mehta about strategies for expanding access to cell therapy for patients. Check out the video below to gain insights from Dr. Mehta on this important topic. #celltherapy #autoimmune #CART
I had the pleasure of interviewing Dr. Amitkumar Mehta, Director of Lymphoma and IEC/CAR T at the University of Alabama at Birmingham (UAB) at #ASH24. Our big question as a firm at this year's ASH is how to get cell therapy to more patients. So, how do we actually do that? We discuss in the video, but highlights include: -Outpatient, with appropriate risk stratification for hospitalization, but eventually moving toward outpatient becoming standard of care for cell therapy delivery -Resources permitting (a big ask, certainly) moving cell therapy (inclusive of hem, solid, non-cancer indications) out of the transplant department into its own dedicated service line. This is not unlike what dedicated theranostic centers like United Theranostics (https://lnkd.in/eaqcc6yM) do for radiopharmaceuticals -Expanding the range of physicians capable of delivering cell therapy and managing cell therapy patients, including specialists like Rheumatologists (e.g., for SLE) and Neurologists (e.g., for MS or MG) -Judiciously expanding cell therapy delivery into receptive non-academic sites based on willingness/motivation from the site, qualified personnel (e.g., HemOncs with cell therapy experience at other sites), and proximity/relationship to existing CAR T centers. Further, manufacturers engaging these sites can of course look to existing pilots (Kite - TN Oncology for example) for insight, but also find insight in how medical / surgical device companies engage their stakeholders when adopting new devices and equipment. Cell & Gene at ZS Jedediah Seltzer, Ph.D. #CART #celltherapy #autoimmune